Conference paper

COGNITIVE IMPAIRMENT IN PARKINSON´S DISEASE

Gerhard Ransmayr ; Department of Neurology and Psychiatry and Faculty of Medicine, Johannes Kepler University Linz, General Hospital of the City of Linz, Linz, Austria

Abstract

Parkinson’s disease is the second most frequent neurodegenerative disorder. There is significantly elevated risk of cognitive
decline and associated neuropsychiatric symptoms.
Dementia may develop insidiously several years after manifestation of Parkinson motor symptoms (dementia associated with
Parkinson’s disease; Parkinson’s disease dementia) or in close temporal relationship (within one year) after onset of motor
symptoms (Dementia with Lewy bodies). There are clinical, pathophysiological and therapeutic similarities between these two
conditions. Men are more frequently affected than women. Risk factor or indicators are advanced age at disease onset, disease
duration, rigidity, akinesia and posture and gait impairment and falls as opposed to tremor dominance, and associated
neuropsychiatric symptoms (depression, apathy, hallucinosis, delirium). Dementia is treatable with cholinesterase inhibitors
(rivastigmine, donepezil), memantine, and adjustment of the pharmacological regimen of parkinsonian motor symptoms.
Concomitant autonomic nervous system symptoms and neuropsychiatric complications warrant early clinical awareness and are
accessible to pharmacological therapy.

Keywords

Parkinson – dementia - dementia with Lewy bodies - review

Hrčak ID:

162558

URI

https://hrcak.srce.hr/162558

Publication date:

15.12.2015.

Visits: 969 *